Company Profile · Healthcare

Becton Dickinson and Company

BDX · US
Exchange
US
Country
USA
IPO date
Jan 1, 1987
Employees
60,000
Website
www.bd.com
Current Price
$143.98
Live · Jun 18, 2026
Baillie Growth Score
40/100
Weak
Intrinsic Value · Three-Tier Range Current price $143.98 Live · Between the conservative and fair ranges

Composite valuation range · conservative $108–$125 / fair $154–$178 / optimistic $217–$249. At $143.98, Between the conservative and fair ranges.

At publication $147.63 (May 24, 2026)

No reports on this stock in your language yet.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

Market cap$39.02B
Revenue (TTM)$22.23B
EBITDA$6.16B
Profit margin5.12%
ROE6.67%
P/E (TTM)24.71
Forward P/E10.49
PEG1.11
EPS$5.73
Dividend yield2.88%
52-week range$125.21 – $184.86
Analyst target$180.69
Analyst rating3.8 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.